重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））(HB002.1T) - 药物靶点：TGFBR2 x VEGFR2_在研适应症：晚期恶性实体瘤，晚期癌症_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

+ [1]

靶点

TGFBR2 x VEGFR2

作用机制

TGFBR2抑制剂(转化生长因子β受体2抑制剂)、VEGFR2拮抗剂(血管内皮细胞生长因子受体2拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评特殊审批 (中国)

关联

4

项与重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））相关的临床试验

CTR20200664 / Completed临床1期

HB002.1T注射液治疗晚期实体瘤患者的安全性，耐受性及药代动力学的I期临床试验

主要目的:评估HB002.1T联合不同化疗方案在晚期实体瘤患者中的耐受性、安全性和药代动力学特点，确定HB002.1T联合不同化疗方案的最大耐受剂量，为II/III期临床研究推荐HB002.1T联合化疗的给药方案。次要目的:评估HB002.1T的免疫原性；按照实体瘤疗效评价标准（RECIST1.1），通过ORR、DCR、DOR和PFS初步评估HB002.1T联合不同化疗方案的抗肿瘤疗效。

开始日期2020-05-22

申办/合作机构

华博生物医药技术（上海）有限公司

NCT04802980 / Recruiting临床1期

A Phase Ib, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety, Tolerability and Pharmacokinetics of HB002.1T in Combination With Chemotherapy in Patients With Advanced Solid Tumors.

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T in combination with different chemotherapy regimens administered to patients with advanced solid tumors.

开始日期2020-04-28

申办/合作机构

华博生物医药技术（上海）有限公司

CTR20181028 / Completed临床1期

重组人血管内皮生长因子受体-抗体融合蛋白注射液治疗晚期实体瘤患者安全性，耐受性及药代动力学I期临床试验

主要目的：研究 HB002.1T 在晚期实体瘤患者中的耐受性、安全性和药代动力学特点，确定剂量限制性毒性（Dose Limited Toxicity，DLT）及最大耐受剂量（Maximal Tolerated Dose，MTD），为后期临床研究推荐合理的给药方案。次要目的：评估 HB002.1T 的免疫原性；按照实体瘤疗效评价标准（RECIST 1.1），通过客观缓解率（ORR）和疾病控制率（DCR）初步评估HB002.1T 的抗肿瘤疗效。

开始日期2018-09-20

申办/合作机构

华博生物医药技术（上海）有限公司

100 项与重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））相关的临床结果

登录后查看更多信息

100 项与重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））相关的转化医学

登录后查看更多信息

100 项与重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））相关的专利（医药）

登录后查看更多信息

9

项与重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））相关的文献（医药）

1993-12-15·Biochemical Journal3区 · 生物学

Two distinct secretory ribonucleases from human cerebrum: purification, characterization and relationships to other ribonucleases

3区 · 生物学

Article

作者: Kishi, K ; Yasuda, T ; Takeshita, H ; Nadano, D

Two RNAases from human cerebrum were purified to an electrophoretically homogeneous state and their molecular masses were 22.0 kDa (tentatively called RNAase HB-1) and 19.0 kDa (RNAase HB-2). Analyses of the amino acid compositions, N-terminal amino acid sequences and catalytic properties of these enzymes provided strong evidence that they were strictly related to the secretory (sec) RNAases, such as the pancreatic enzyme, very similar immunologically to urinary sec RNAase, but clearly distinguishable from urinary non-secretory (nonsec) RNAase. There were several differences between HB-1 and HB-2, namely their immunological reactivities with specific antibodies, heat-stabilities, attached carbohydrate moieties and molecular masses. In particular, HB-2 appeared to be nonglycosylated, in view of its lack of affinity for several conjugated lectins, the absence of hexosamine and no change in electrophoretic mobility before and after peptide:N-glycosidase F digestion, whereas HB-1 and human sec RNAases purified from kidney, pancreas and urine all appeared to be glycosylated, as they moved to the same position as HB-2 when electrophoresed after glycosidase digestion. An antibody against urinary sec RNAase inhibited 75% and 20% of the total activity of the crude cerebral extract against RNA at pH 8.0 and 6.0 respectively, whereas an antibody against urinary nonsec RNAase had no such inhibitory effect. These findings suggest that yet another type(s) of cerebral RNAase, which is unable to cross-react immunologically with sec and nonsec RNAases, may exist. Two RNAases corresponding to HB-1 and HB-2 were identified in fresh cerebrospinal fluid.

1990-08-01·Microbial Pathogenesis3区 · 医学

Induction of an immune response to the porin of Haemophilus influenzae type b by monoclonal anti-idiotypic antibodies

3区 · 医学

Article

作者: Bernard R. Brodeur ; Josée Hamel

Monoclonal anti-idiotypes were generated against monoclonal antibody (mAb) Hb-2 which recognized a highly conserved epitope on the outer membrane porin protein from Haemophilus influenzae type b (Hib). Four hybridomas reacting with F(ab') 2 fragments of Hb-2 were selected and characterized. Inhibition studies using syngeneic anti-anti-idiotypic antisera suggested that at least three different antigenic determinants on Hb-2 were recognized by these monoclonal anti-idiotypes. The binding of each anti-idiotype to Hb-2 was inhibited by Hb-2 whereas the reaction was not affected by any other anti-Hib mAb. Complete inhibition of the binding of anti-idiotype to the idiotype could be achieved with 10 micrograms of total outer membrane protein (OMP) from Hib suggesting that the anti-idiotypes might be directed against paratope-associated idiotypes. Outer membrane antigens not recognized by mAb Hb-2 did not inhibit the reaction. Furthermore, the pre-incubation of Hb-2 with each anti-idiotype specifically prevented the reaction of Hb-2 with its antigen. Antibodies with specificity for the porin were generated in guinea pigs immunized with anti-idiotypes AHb-22 and AHb-23. This study indicates that these particular monoclonal anti-idiotypes may be used as an antigen substitute for the porin of Hib in a xenogeneic species.

1988-01-01·Acta physiologica et pharmacologica Bulgarica

Study of the participation of the dopaminergic transmission system in the effects of two newly synthesized barbiturates.

Article

作者: Getova, D ; Markovska, V

The effects of two newly synthesized barbiturates--HB-7 (2-hydroxylamino-5-ethyl-5-sec. pentylbarbituric acid) and HB-2 (2-hydroxylamino-5-ethyl-5-propylbarbituric acid--on models of apomorphine stereotypy and haloperidol catalepsy were investigated in experiments on male rats and mice. The test drugs used were phenobarbital (PB)--in stereotypy and catalepsy, and diphenylhydantoin (DPH)--in catalepsy. HB-7 changes the stereotypy considerably: it developed faster and disappeared faster than in the control group. Phenobarbital had a weaker effect on the intensity and duration of the stereotypy. Catalepsy was induced with haloperidol in doses of 1 and 2 mg/kg. HB-7 and HB-2 weakened haloperidol catalepsy, compared with PB and DPH. The faster occurrence of apomorphine stereotypy and the weakening of the haloperidol-induced catalepsy under the effect of the two hydroxyl-amine derivatives of barbituric acid suggest an effect on the cerebral dopaminergic transmission. This effect may be mediated through the effect of HB-7 on DA-ergic transmission or through the GABA-ergic transmission in the brain structures responsible for these behavioural reactions.

100 项与重组人血管内皮生长因子受体-抗体融合蛋白（华博生物医药技术（上海））相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	临床1期	中国	上海华奥泰生物药业股份有限公司	2021-11-17
晚期恶性实体瘤	临床1期	中国	华博生物医药技术（上海）有限公司	2020-04-28
晚期癌症	临床1期	中国	华博生物医药技术（上海）有限公司	2018-09-20
卵巢癌	临床前	中国	上海华奥泰生物药业股份有限公司	2021-11-17
胆管上皮癌	药物发现	中国	上海华奥泰生物药业股份有限公司	2021-11-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04802980 (ASCO2023) 人工标引	临床1期	HR阳性/HER2低表达实体瘤	68	chemotherapy+HB002.1T	(範糧衊艱齋艱窪選網範) = 遞構遞憲餘糧窪網醖鏇鏇選繭觸鹽鑰選鹽鬱窪 (獵齋選鬱製襯觸憲網齋 ) 更多	积极	2023-05-26
				chemotherapy+HB002.1T (ovarian cancer)	(壓餘鑰艱艱構選網淵鏇) = 遞廠選鏇膚膚膚夢淵餘鏇遞蓋蓋簾襯獵襯廠鹹 (齋廠憲齋壓壓鑰鏇網壓 ) 更多